Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
br Perspectives and challenges Previously the main focus of
2024-03-01

Perspectives and challenges Previously, the main focus of development of adenosine targets for pain was on A1Rs, due to prominent antinociception in multiple preclinical models and preliminary observations in human trials. However, delivery of agonists can be limited by other (e.g. cardiovascular
-
br Experiment br Results and discussion br
2024-03-01

Experiment Results and discussion Conclusion Introduction Tuberculosis (TB) is a chronic specific bacterial infection caused by bacteria of the Mycobacterium tuberculosis [1]. TB remains one of the deadliest diseases in the world. It is the second leading infectious cause of death after
-
We have previously reported that
2024-03-01

We have previously reported that interfering with Fmoc-Hyp-OH assembly dynamics by knocking down cofilin-1 in hMSCs increased polymerized actin that promoted osteoblast cell differentiation through a mechanism of enhancing focal adhesion kinase (FAK), p38 and c-Jun N-terminal kinase (JNK) signaling
-
The acetylcholinesterase AChE inhibitor tacrine THA exerts
2024-03-01

The acetylcholinesterase (AChE) inhibitor, tacrine (THA), exerts neuroprotective effects in time- and does-dependent manners against glutamate neurotoxicity (Takada-Takatori et al., 2006a, 2006b) and amyloid-β protein toxicity in PC12, a pheochromocytoma line (Wang et al., 2002; Xiao et al., 2000).
-
Whereas more research is needed to identify the precise
2024-03-01

Whereas more research is needed to identify the precise mechanism by which FIN exerts its antidyskinetic effect, the GZD824 that it can negatively modulate dopaminergic transmission is also supported by our previous findings. Indeed, we have previously shown that FIN completely reversed the behavior
-
Significant reductions in GYN cancer patient mortality and m
2024-02-29

Significant reductions in GYN cancer patient mortality and morbidity rates require treatments that proactively prevent and reverse resistance to chemotherapy and radiation. Combining chemotherapy and radiation with inhibitors of key DDR proteins targets is likely to enhance the ability of genotoxic
-
Enhanced arginase activity and the
2024-02-29

Enhanced arginase activity and the resultant decreases in L-arginine levels can also impair T cell mediated immune function and allow tumor growth by limiting the supply of L-arginine needed for the formation of cytotoxic levels of NO by iNOS [10]. Increased arginase expression/activity may also lim
-
The Nagoya Heart Study enrolled patients with hypertension a
2024-02-29

The Nagoya Heart Study enrolled patients with hypertension and type 2 diabetes or impaired TMC125 tolerance (12). Patients were randomized to valsartan- or amlodipine-based regimens with a BP target of ≤130/80 mmHg. The primary outcome was a composite of sudden cardiac death, myocardial infarction,
-
Pathological angiogenesis occurs when an imbalance of
2024-02-29

Pathological angiogenesis occurs when an imbalance of endogenous proangiogenic and antiangiogenic factors occurs. Although the focus of angiogenesis-related drug development has been geared to the discovery of antiangiogenic compounds for use in pathologies where excessive angiogenesis occurs (cance
-
br Acknowledgments This work was
2024-02-29

Acknowledgments This work was supported by grants from the “Agence Nationale de la Recherche” ANR-09-CESA-006 program, the Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (Anses, Project n° 2012-2-077) and the Interdisciplinary Program “Longévité et Viei
-
Perhaps the first evidence of AMPKs
2024-02-29

Perhaps the first evidence of AMPKs therapeutic ability in DM1 came from Thomas Cooper’s laboratory where they demonstrated that insulin-independent glucose uptake was unaffected in human DM1 muscle LY2228820 treated with MET, an AMPK activator and first-line therapy for type 2 diabetes mellitus [76
-
The glutamate receptors are important to the glioma
2024-02-29

The glutamate receptors are important to the glioma LY364947 from escaping the excitotoxicity under physiological conditions. There are three subtypes of ionotropic glutamate receptors, including NMDA, kainate, and AMPA receptors, which are relating to diverse Ca2+ permeability. Glioma cells also e
-
br Discussion Herein we demonstrate that mice deficient in
2024-02-29

Discussion Herein, we demonstrate that mice deficient in L-12/15 LO are more sensitive to 3-NP-induced toxicity although a substantial individual variability in striatal lesion size in response to 3-NP in both genotypes was observed. This variability is not atypical; several studies demonstrate s
-
To date defining the prognostic
2024-02-29

To date, defining the prognostic impact of molecular drivers of early-stage NSCLC has been challenging due to the relative rarity of these subsets and the redefinition of comparator arms over time as understanding of the molecular drivers of NSCLC evolved. Indeed, use of molecularly heterogeneous co
-
br Conclusion br Conflict of interest br Acknowledgements br
2024-02-29

Conclusion Conflict of interest Acknowledgements Introduction Human salivary aldehyde dehydrogenase (hsALDH) (E.C. 1.2.1.5) is the first line of defence against toxic aldehydes in the oral cavity. HsALDH is primarily a dimeric, class 3 ALDH (ALDH3A1) specific for aromatic and long/medium
15387 records 199/1026 page Previous Next First page 上5页 196197198199200 下5页 Last page